Re-Assembled Botulinum Neurotoxin Inhibits CNS Functions without Systemic Toxicity by Ferrari, Enrico et al.
Toxins 2011, 3, 345-355; doi:10.3390/toxins3040345 
 
toxins
ISSN 2072-6651 
www.mdpi.com/journal/toxins 
Article 
Re-Assembled Botulinum Neurotoxin Inhibits CNS Functions 
without Systemic Toxicity  
Enrico Ferrari 
1, Elizabeth S. Maywood 
1, Laura Restani 
2, Matteo Caleo 
2, Marco Pirazzini 
3, 
Ornella Rossetto 
3, Michael H. Hastings 
1, Dhevahi Niranjan 
1, Giampietro Schiavo 
4 and  
Bazbek Davletov 
1,* 
1  Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK;  
E-Mails: eferrari@mrc-lmb.cam.ac.uk (E.F.); emaywood@mrc-lmb.cam.ac.uk (E.S.M.);  
mha@mrc-lmb.cam.ac.uk (M.H.H.); niranjan@mrc-lmb.cam.ac.uk (D.N.) 
2  Istituto di Neuroscienze, Consiglio Nazionale delle Ricerche, 56100 Pisa, Italy;  
E-Mails: restani@in.cnr.it (L.R.); caleo@in.cnr.it (M.C.)  
3  Dipartimento di Scienze Biomediche, Università  di Padova, 35121 Padova, Italy;  
E-Mails: marco.pirazzini@studenti.unipd.it (M.P.); ornella.rossetto@unipd.it (O.R.) 
4  Molecular NeuroPathoBiology Laboratory, Cancer Research UK London Research Institute, 
London WC2A 3LY, UK; E-Mail: giampietro.schiavo@cancer.org.uk 
*  Author to whom correspondence should be addressed; E-Mail: bazbek@mrc-lmb.cam.ac.uk;  
Tel.: +44-1-223-402-009; Fax: +44-1-223-402-310. 
Received: 24 February 2011; in revised form: 18 March 2011 / Accepted: 23 March 2011 /  
Published: 24 March 2011 
 
Abstract: The therapeutic potential of botulinum neurotoxin type A (BoNT/A) has recently 
been  widely  recognized.  BoNT/A  acts  to  silence  synaptic  transmission  via  specific 
proteolytic  cleavage  of  an  essential  neuronal  protein,  SNAP25.  The  advantages  of  
BoNT/A-mediated  synaptic  silencing  include  very  long  duration,  high  potency  and 
localized action. However, there is a fear of possible side-effects of BoNT/A due to its 
diffusible nature which may lead to neuromuscular blockade away from the injection site. 
We  recently  developed  a  ―protein-stapling‖  technology  which  allows  re-assembly  of 
BoNT/A from two separate fragments. This technology allowed, for the first time, safe 
production of this popular neuronal silencing agent. Here we evaluated the re-assembled 
toxin in several CNS assays and assessed its systemic effects in an animal model. Our 
results  show that the re-assembled toxin is potent in inhibiting CNS function at 1 nM 
concentration  but  surprisingly  does  not  exhibit  systemic  toxicity  after  intraperitoneal 
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injection  even  at  200  ng/kg  dose.  This  shows  that  the re-assembled toxin  represents  a 
uniquely safe tool for neuroscience research and future medical applications. 
Keywords:  botulinum  neurotoxin;  nervous  system;  protein  engineering;  synapse; 
SNAREs; BOTOX; BITOX 
 
1. Introduction 
The  study  of  the  nervous  system  of  vertebrates,  and  ultimately  human  patients,  requires 
development  of  tools  for acute, reversible and preferably long-term  silencing of selected neuronal 
subpopulations. One way to meet these requirements would be to re-engineer botulinum neurotoxins 
(BoNTs)  [1–3].  These  toxins  target  a  variety  of  synapses,  enter  presynaptic  terminals  and  then 
specifically cleave SNARE proteins to stop neurotransmitter release [4–7]. Restoration of neuronal 
activity takes place when toxin is degraded and the cleaved protein is replaced in the active zones of 
presynaptic terminals by the de novo synthesized SNARE protein [8]. Remarkably, the seven known 
serotypes of BoNTs cause blockade of different durations, with type A causing the longest silencing 
(4–6 months) in humans, whereas type E causes the shortest blockade (2–4 weeks) [9,10]. BoNTs 
became  important  research  and  medical  tools  due  to  their  high  potency,  since  reversible  synaptic 
blockade can be achieved by injection of only few picograms of BoNTs in the desired location [11]. 
While it is possible to produce pure forms of BoNTs using normal E. coli expression systems, only a 
few labs are equipped to make full BoNTs due to safety reasons—not least their potential toxicity upon 
accidental injection or possible environmental contamination. The high cost of commercial BoNTs and 
these safety issues significantly hampered development of these silencing agents for the benefit of 
neurobiology and medicine. Clearly, new approaches which could solve the safety issues and also 
allow production of new functional variants of BoNTs could go a long way in meeting the demand for 
acute, on-demand neuronal silencing [12]. 
We recently reported a novel way to assemble large proteins from individual functional units [13]. 
We  utilized  the  ability  of  three  SNARE  polypeptides—syntaxin,  SNAP25  and  synaptobrevin—to 
assemble in an irreversible manner into a well-defined tetra-helical complex [14]. Firstly, we fused 
SNAP25 to the light chain/translocation domain (LcTd) of BoNT type A (BoNT/A) and, secondly, 
synaptobrevin  polypeptide to the receptor-binding domain (Rbd) of BoNT/A. Both fusion proteins 
could  be expressed and purified to homogeneity. Next, we made a synthetic syntaxin peptide and 
demonstrated that addition of this, so-called ―staple‖ was sufficient to assemble LcTd and Rbd into a 
new entity. The structural evaluation of BoNT/A (PDB 3BTA) [15] and the SNARE assembly (PDB 
1SFC)  [14]  suggests  that  the  re-assembled  BoNT/A  could  be  substantially  longer  than  the  native 
molecule (Figure 1a–c). The re-assembled BoNT/A demonstrated similar efficiency to that of native 
BoNT/A in cleaving SNAP25 and inhibiting neurotransmitter release in CNS neurons but exhibited a 
reduced potency in blocking neuromuscular junctions [13]. Here, we report our new results on the 
effects of the re-assembled BoNT/A (for brevity referred to as BiTox, for Binary Toxin) on CNS 
neurons and also provide toxicological evaluation in an animal model. Our results indicate that BiTox 
does not display systemic toxicity and therefore represents a promising selective CNS silencing agent. Toxins 2011, 3                         
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Figure 1. (a) A drawing outlining the three domains of BoNT/A (PDB 3BTA) [15]: the 
Light chain (Lc) in red, the Translocation domain (Td) in grey and the Receptor binding 
domain  (Rbd)  in  yellow;  (b)  The  three  components  used  for  assembly  of  BiTox  are  
LcTd-SNAP25, brevin-Rbd and the syntaxin peptide; (c) The assembled BiTox consists of 
the  same  three  domains  of  the  native  BoNT/A  but  with  the  SNARE  stapling  system 
between  Td  and  Rbd  domains;  (d)  Coomassie-stained  SDS-PAGE  gel  showing  the 
assembly of LcTd-SNAP25, brevin-Rbd and the syntaxin peptide into a single entity which 
represents the BiTox. The assembly reaction with all components at 5 μM concentration is 
complete within 30 min. 
 
2. Results 
Figure  1d  shows  the  typical  assembly  of  BiTox  from  individual  components  visualized  in  a 
Coomassie-stained gel. Judging by the disappearance of reactants after 30 min and appearance of the 
high-molecular weight BiTox, it is clear that the assembly reaction is highly efficient. 
The ability of BoNT/A to silence synaptic transmission is based on its proteolytic activity to remove 
nine  C-terminal  amino  acids  from  SNAP25  [4].  Therefore,  the first  step in  the evaluation  of any 
engineered BoNT/A requires determination of the SNAP25 cleavage. A number of antibodies have 
been developed to monitor the BoNT/A-mediated SNAP25 cleavage. In the first instance, we used a  
C-terminal SNAP25 antibody that recognizes only the full-length molecule and evaluated the activity 
of BiTox in mouse cerebellar granule neurons. 6 days after plating, granule neurons were incubated for 
24 h with the indicated dose of BiTox. After incubation with the toxin, cells were lysed and probed by 
western immunoblotting using the C-terminal SNAP25 antibody. Figure 2 shows that BiTox efficiently 
cleaves SNAP25 in cultured cerebellum granule neurons at 1 nM concentration. Toxins 2011, 3                         
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Figure  2.  Western  blot  showing  cleavage  of  SNAP25  in  cultured  cerebellum  granule 
neurons  by  0.1–10  nM  BiTox  and  BoNT/A  after  24  h  at  37  ° C.  The  normal 
immunostaining levels of SNAP25 and synaptobrevin (brevin) are shown in the untreated 
sample (0 nM). The SNAP25 antibody recognizes only the full-length protein but not the 
cleaved product. 
 
Next, we investigated whether BiTox is active when injected directly into the brain, i.e., not in bath 
conditions. Rat visual cortex was injected with either BiTox or vehicle, injection volume being 1 µL. 
Tissues  were  dissected  after  2  days  and  subjected  to  western  immunoblot  analysis  for  cleaved  
SNAP-25. Since we anticipated that only a small area of the cortex will internalise BiTox and thus 
there will be an abundance of uncleaved SNAP25, we utilized an anti-peptide antibody that recognizes 
only the cleaved end of SNAP25 (amino acids TRIDEANQ) [16]. Figure 3 shows that 1 µL injection 
of 20 nM BiTox (4 ng) results in a detectable cleavage of SNAP25 within the cortex thus necessitating 
future behavioral and functional tests. 
Figure 3. Immunoblot showing cleaved SNAP25 following intracortical injection of BiTox 
(4 ng). A 24 kDa band corresponding to cleaved SNAP25 is detected only in the tissue 
injected  with  BiTox,  but  not  vehicle  (Control),  demonstrating  that  the  injection  of  the  
re-assembled toxin results in the cleavage of its substrate SNAP25. α-Tubulin was used as 
internal standard for protein loading. 
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To evaluate efficacy of BiTox to suppress a physiological function, we prepared organotypic slices 
of suprachiasmatic nucleus (SCN) from neonatal mice (10 day of age) carrying a knock-in mutation of 
the Period2 circadian clock gene that encodes a Per2-luciferase fusion protein [17]. Bioluminescence 
signals were recorded for 72 h prior to application of BiTox to confirm robust circadian oscillations. 
Recording continued for a further 9 days after bath addition of BiTox at indicated concentrations.  
Figure 4a shows that the addition of 0.8 nM BiTox halved the amplitude of the circadian oscillation 
within 48 h and by day 7 the peak bioluminescence was diminished to ~20% of the untreated sample, 
similarly to native BoNT/A [18]. Titration of BiTox activity at day 2 demonstrated IC50 being ~1 nM  
(Figure 4b). 
Figure 4. Suppression of circadian bioluminescence rhythms of suprachiasmatic nucleus 
(SCN)  slices  by  BiTox.  (a)  The  amplitude  of  the  gene  expression  rhythms  decreases 
dramatically following application of 0.8 nM BiTox. The luminescence peak levels were 
averaged and plotted as a percentage comparison with the untreated control levels (100%). 
Day 0 corresponds to the day of BiTox application; (b) Dose-dependence of BiTox-induced 
reduction in the luminescence peak levels 2 days following BiTox application. 
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Peripheral administration of  native BoNT/A causes neuromuscular blockade, which  may lead to 
death  due  to paralysis  of the diaphragm  [19,20]. Interestingly, we previously noticed that BiTox 
exhibits a reduced potency at neuromuscular junctions  [13]  and  the above  intracerebral injections 
demonstrated no lethality, thus it was important to assess its systemic toxicity in a dose-dependent way. 
We evaluated the effect of intraperitoneal injections of BiTox on  the musculature of the limbs and 
survival [21]. Following injections, the appearance of weakness of the musculature of the limbs either 
ipsilateral to the injection point or bilateral was monitored over 4 days. In parallel, native BoNT/A was 
injected. Figure 5 shows that while injections of BoNT/A  were lethal even at 2 ng/kg, we have not 
observed  obvious  signs  of  muscle  weakness  in the case of BiTox within 4 days at doses up to   
200 ng/kg. We conclude that BiTox does not possess the systemic toxicity evident in the case of 
native BoNT/A.  Toxins 2011, 3                         
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Figure 5. The mouse toxicity of BiTox was compared to that of native BoNT/A following 
intraperitoneal  injection.  Injections  of  BoNT/A  at  2, 5, 10, 20 ng/kg result  in  lethality 
within 24 h, while no symptoms were detected after 96 h (the endpoint of the experiment) 
after  i.p.  injection  of  BiTox  (20,  50,  100,  200  ng/kg  doses),  even  at  the  highest 
concentration. 
 
3. Discussion and Conclusions 
Our  new  results  show  that  BiTox  can  efficiently  affect  CNS  activities  without  causing 
neuromuscular paralysis. Such paradoxical differential action of BiTox has not been anticipated and 
thus requires explanation. It is highly unlikely that native BoNT/A preparations carry an unidentified 
component that specifically targets NMJ; indeed fully recombinant version of BoNT/A (e.g., produced 
by  Ipsen  or  Merz)  is  a  single  polypeptide  which  has  a  paralytic  activity  comparable  to  the  
Clostridia-derived neurotoxin [22]. We favor the possibility that our re-assembled toxin retains the 
ability to enter central synapses but is inefficient in penetrating NMJ. The major difference between the 
native toxin and BiTox is that the linking mechanism results in the placement of the SNARE helical 
bundle (~10 nm in length, see PDB 1SFC) [14] between the receptor-binding domain (~5 nm, PDB 
3BTA) and the light chain together with the translocation domain (~8 nm, PDB 3BTA) [15], thus 
nearly doubling the size of neurotoxin. Such an extended molecule may have a compromised ability to 
enter into the tight cleft of NMJs which possess hundreds of active zones extending over millimeters in 
length. In addition, NMJs are often covered by Schwann cell and other capping cells [23], which may 
also play a role in the inability of BiTox to enter the NMJ. In contrast, most CNS synapses contain a 
single active zone at presynaptic terminals and would be topologically more accessible even in the case 
of the elongated BiTox. It is also possible that BiTox has a compromised ability to translocate inside 
the motor nerve terminals for an unknown reason. Although the rationale of the differential action of 
BiTox  at  the  NMJ  and  central  synapses  is  presently  unclear,  the  potential  implications  of  this 
difference are of both biological and medical importance. 
Botulinum toxin  variants that specifically affect neurons and do not paralyze muscles could be 
invaluable when a reversible silencing of only CNS neurons is required [24,25]. For example, topical 
intradermal application of BoNT/A (sold under pharmaceutical names BOTOX, Dysport and Xeomin) Toxins 2011, 3                         
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has recently been used to alleviate pain conditions [26] and was approved for migraine treatment both 
in the USA and the UK. It is believed that the anti-nociceptive action of topical BoNT/A is due to the 
blockade of peripheral terminals of primary afferents [26]. However, because BoNT/A also causes 
local neuromuscular paralysis, it may be advantageous to have an improved version of the toxin which 
can only act on sensory terminals and not on NMJs. Another potential use of botulinum neurotoxins 
lies in the treatment of epilepsy [25]. Injections of botulinum neurotoxin into defined areas of the brain 
result in a long-term reversible silencing of the epileptic focus in animal models [27,28]. Clearly, in 
such CNS disorders the NMJ paralyzing ability of BoNT/A is not only redundant but also could be 
potentially dangerous if the injected native toxin enters the systemic circulation. 
It  is  worth  noting  that  the  safety  issues  surrounding  native  BoNT/A  significantly  hamper 
development of this neurotoxin for the benefit of neurobiology and medicine. Clearly, new approaches 
that could allow development of safer versions of BoNT/A would go a long way towards meeting the 
need  for  acute,  on-demand  neuronal  silencing.  The  assembly  of  functional  BiTox  from  two 
independent and non-toxic parts, which have to be stapled together using a synthetic peptide, provides 
several safety levels against possible abuse. Our current results now demonstrate that the re-assembled 
neurotoxin  possesses  novel  functional  characteristics  and  can  be  used  for  silencing  CNS  neurons 
without fear of causing generalized paralysis.  
4. Experimental Section 
4.1. Plasmids, Proteins Purification and Assembly 
Plasmids  for  the  expression  of  LcTd-SNAP25  and  brevin-Rbd  were  previously  described  [13]. 
Briefly, all proteins were expressed in BL21 strain of E. coli as GST C-terminal fusions cleavable by 
thrombin. Proteins fused to GST were purified on glutathione Sepharose beads (GE Healthcare) and 
eluted  from  beads  in  20  mM  Hepes,  pH  7.3,  100  mM  NaCl  (Buffer  A)  using  thrombin.  Further 
purification  has  been  achieved  by  gel  filtration  using  a  Superdex  200  10/200  GL  column  (GE 
Healthcare).  The  BiTox  was  assembled  by  mixing  the  SNARE-tagged  proteins  with  the  syntaxin 
peptide for 30 min at 20 °C , each component at 5 μM concentration. To visualize SNARE assemblies, 
SDS-PAGE was performed at 4 ° C, and the gels were stained with Coomassie blue. 
4.2. Cerebellum Granule Neurons and Immunoblot 
Rat  cerebellar  granule  neurons  (CGNs)  were  prepared  from  6  days  neonatal  rats  as  previously 
described [29]. Briefly, fresh cerebella were disrupted mechanically in presence of trypsin and DNase I 
and the cells plated onto 24 well culture plates functionalized with poly-L-lysine (10 μg/mL). Cultures 
were maintained  at  37 ° C, 5% CO2, 95% humidity in BME supplemented with 10%  fetal bovine 
serum, 25 mM KCl, 2 mM glutamine an 50 μg/mL gentamycin. To arrest growth of non-neuronal cells, 
cytosine arabinoside (10 μM) was added to the medium 18–24 h after plating. 6 days after plating, 
CGNs were incubated for 24 h at 37 ° C with the indicated dose of either BiTox or BoNT/A (Figure 2) 
diluted in BME supplemented with 10% FBS and 25 mM KCl. After incubation with the toxin, cells 
were directly lysed in the wells with Laemmli buffer containing protease inhibitors (complete Mini 
EDTA-free,  Roche)  and  separated  by  SDS-PAGE  electrophoresis  for  Western  immunoblotting. Toxins 2011, 3                         
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Primary antibodies against SNAP25 and synaptobrevin were incubated overnight at 4 ° C, washed three 
times  with  PBS-Tween,  and  incubated  with  secondary  antibodies  conjugated  to  horse  radish 
peroxidase. After three washes with PBS-Tween and one with PBS, visualization was carried out using 
enhanced chemiluminescence kit (ECL, GE Healthcare). 
4.3. Western Immunoblotting of Rat Cortex Following BiTox Injection 
Rats received 4 ng BiTox injection into the visual cortex (1 μL of 20 nM). Visual cortices were 
dissected  two  days  following  neurotoxins  injection.  Proteins  were  extracted  with  lysis buffer (1% 
Triton  X-100,  10%  glycerol,  20  mM  Tris-HCl,  pH  7.5,  150  mM  NaCl,  10  mM  EDTA,  0.1  mM 
Na3VO4, 1 μg/mL leupeptin, 1 μg/mL aprotinin, and 1mM PMSF), and the total concentration of the 
samples was assessed with a protein assay kit (Bio-Rad) using a bovine serum albumin-based standard 
curve.  Immunoblotting  was  performed  as  described  previously  [30,31].  The  antibody  against  
BoNT/A-cleaved  SNAP-25  was  characterized  in  [31].  Protein  extracts  were  separated  by 
electrophoresis  and  blotted,  and  filters  were  incubated  with  primary  antibodies  overnight  at  4  ° C  
(anti-cleaved  SNAP-25,  1:500  dilution).  Blots  were  then  reacted  with  HRP-conjugated  secondary 
antibodies  (Jackson  ImmunoResearch)  and  developed  by  ECL  (GE  Healthcare).  Filters  were  also 
probed  with  anti-α-tubulin  monoclonal  antibody  (1:10,000  dilution;  Sigma),  which  serves  as  an 
internal standard for protein quantification. 
4.4. Bioluminescent Circzadian Recordings 
Organotypic slices of suprachiasmatic nucleus (SCN) were made from neonatal mice (10 days of 
age) carrying a knock-in mutation of the Period2 circadian clock gene that encodes a Per2-luciferase 
fusion  protein  [17].  Per2-driven  bioluminescence  was  recorded  using  photomultiplier  tubes 
(Hamamatsu) as described elsewhere [32]. After 72 h to confirm robust circadian oscillations, slices 
were bath treated with either vehicle or BiTox at the concentrations given in Figure 3 (n = 3 per group). 
Recording continued for a further 9 days. The amplitude and precision of the gene expression rhythms 
were calculated using BRASS software (courtesy of A. Millar, University of Edinburgh, Edinburgh,  
United Kingdom). 
4.5. Toxicity Assessment 
Adult C57 BL6 mice (60–90 days of age; average 24 g) were injected intraperitoneally with the 
indicated doses (two mice/dose) of BiTox and native BoNT/A diluted 0.1% mouse serum albumin in 
PBS (injection volume 140–210 μL). Animals were transferred back in the cage and monitored every  
6  h  for  4  days.  The  endpoint  of  the  experiment  was  either  the  appearance  of  weakness  of  the 
musculature of the limbs ipsilateral to the injection point or bilateral. Surviving animals were sacrificed 
after 4 days. All experiments were carried out under license from the UK Home Office in accordance 
with the Animals (Scientific Procedures) Act 1986 and following approval from the Cancer Research 
UK Ethical Review Committee. Toxins 2011, 3                         
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